Author

Matthieu Meryet‐Figuière

InsermORCID 0000-0001-8001-6114Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Assay:organoid / primary culture· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Louis‐Bastien WeiswaldiD· 3 shared Céline VillenetiD· 2 shared Émilie Brotin· 2 shared Florence GiffardiD· 2 shared Guillaume Desmartin· 2 shared Jean‐Pascal MenebooiD· 2 shared Jordane DivouxiD· 2 shared Laurent PoulainiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Louis‐Bastien WeiswaldORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyEuropean Journal of Medicinal Chemistry ReportsPeer-reviewedJul 30, 2026

Integrative in silico and experimental identification of non-covalent UBE2N inhibitors enhancing PARP inhibitor sensitivity

Côme Ghadi, Shafi Ullah Khan, Léonie Ibazizene…·Jana Sopková‐de Oliveira Santos

The paper identifies two non-covalent UBE2N inhibitors, CERMN-2 and CERMN-16, which enhance PARP inhibitor sensitivity in ovarian cancer cells.

1 citation

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMar 24, 2026

Predicting Head and Neck Squamous Cell Carcinoma outcomes using long-term Patient-Derived Tumor Organoids

Marion Perréard, Jordane Divoux, Félicie Perrin…·Louis‐Bastien Weiswald

This study uses patient-derived tumor organoids to predict HNSCC patient outcomes, finding strong associations between organoid responses to cisplatin and X-rays and clinical prognosis.

DOI 10.64898/2026.03.22.713356

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyJournal of Experimental & Clinical Cancer ResearchPeer-reviewedOct 7, 2025

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response

Lucie Thorel, Énora Dolivet, Pierre‐Marie Morice…·Laurent Poulain

This study establishes patient-derived ovarian cancer organoids that mimic tumor characteristics and drug responses, showing potential for precision medicine.

14 citationstop 3%

humanorganoid / primary culture

𝕏 PostBluesky